| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccines | 5 | 2015 | 97 | 1.790 |
Why?
|
| Smallpox Vaccine | 5 | 2013 | 14 | 1.520 |
Why?
|
| Meningococcal Vaccines | 3 | 2021 | 28 | 1.240 |
Why?
|
| Epidural Abscess | 2 | 2018 | 9 | 1.180 |
Why?
|
| Anthrax | 8 | 2012 | 13 | 1.180 |
Why?
|
| Communicable Disease Control | 3 | 2015 | 38 | 1.060 |
Why?
|
| Meningitis, Meningococcal | 2 | 2014 | 10 | 0.860 |
Why?
|
| Personal Protective Equipment | 2 | 2020 | 28 | 0.850 |
Why?
|
| Quality Improvement | 2 | 2017 | 425 | 0.830 |
Why?
|
| Smallpox | 4 | 2009 | 9 | 0.760 |
Why?
|
| Meningococcal Infections | 1 | 2021 | 27 | 0.730 |
Why?
|
| Bioterrorism | 5 | 2008 | 11 | 0.720 |
Why?
|
| Neisseria meningitidis | 2 | 2021 | 104 | 0.710 |
Why?
|
| Materials Management, Hospital | 1 | 2020 | 2 | 0.700 |
Why?
|
| HIV-1 | 15 | 2002 | 705 | 0.690 |
Why?
|
| Ventilators, Mechanical | 1 | 2020 | 31 | 0.680 |
Why?
|
| Accountable Care Organizations | 1 | 2020 | 59 | 0.660 |
Why?
|
| Infection Control | 1 | 2020 | 96 | 0.640 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 315 | 0.620 |
Why?
|
| Military Medicine | 2 | 2009 | 11 | 0.580 |
Why?
|
| Bacterial Toxins | 4 | 2007 | 60 | 0.580 |
Why?
|
| Spinal Diseases | 1 | 2017 | 47 | 0.570 |
Why?
|
| Early Diagnosis | 1 | 2017 | 90 | 0.570 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 187 | 0.560 |
Why?
|
| Bacillus anthracis | 4 | 2011 | 12 | 0.560 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 199 | 0.550 |
Why?
|
| Mass Vaccination | 2 | 2014 | 9 | 0.540 |
Why?
|
| Clinical Protocols | 1 | 2017 | 134 | 0.540 |
Why?
|
| Medicare | 1 | 2020 | 600 | 0.530 |
Why?
|
| Models, Statistical | 1 | 2018 | 307 | 0.520 |
Why?
|
| Needles | 2 | 2013 | 63 | 0.520 |
Why?
|
| Virology | 2 | 2013 | 13 | 0.510 |
Why?
|
| Patient Care Team | 2 | 2017 | 330 | 0.510 |
Why?
|
| Military Personnel | 4 | 2009 | 97 | 0.510 |
Why?
|
| Humans | 58 | 2021 | 59471 | 0.490 |
Why?
|
| Pandemics | 1 | 2020 | 609 | 0.490 |
Why?
|
| Hospital Medicine | 1 | 2015 | 7 | 0.480 |
Why?
|
| Teaching Rounds | 1 | 2015 | 11 | 0.480 |
Why?
|
| Antigens, Bacterial | 3 | 2007 | 214 | 0.480 |
Why?
|
| Vaccination | 2 | 2015 | 337 | 0.480 |
Why?
|
| Poliomyelitis | 1 | 2014 | 3 | 0.460 |
Why?
|
| Disease Eradication | 1 | 2014 | 3 | 0.460 |
Why?
|
| HIV Infections | 10 | 2002 | 920 | 0.450 |
Why?
|
| Length of Stay | 1 | 2017 | 768 | 0.440 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 1022 | 0.430 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 421 | 0.430 |
Why?
|
| Disease Outbreaks | 2 | 2012 | 104 | 0.410 |
Why?
|
| Tobacco Mosaic Virus | 1 | 2012 | 8 | 0.400 |
Why?
|
| Plant Diseases | 1 | 2012 | 11 | 0.400 |
Why?
|
| Proprotein Convertases | 1 | 2011 | 5 | 0.390 |
Why?
|
| Aging | 1 | 2018 | 723 | 0.390 |
Why?
|
| Physician's Role | 2 | 2003 | 120 | 0.380 |
Why?
|
| Vaccinia virus | 2 | 2008 | 71 | 0.380 |
Why?
|
| Sepsis | 1 | 2013 | 280 | 0.340 |
Why?
|
| History, 20th Century | 4 | 2012 | 226 | 0.330 |
Why?
|
| Communicable Diseases | 2 | 2011 | 82 | 0.320 |
Why?
|
| Nucleic Acid Amplification Techniques | 3 | 2013 | 27 | 0.310 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 2038 | 0.310 |
Why?
|
| Virulence Factors | 2 | 2007 | 84 | 0.290 |
Why?
|
| RNA, Viral | 4 | 2013 | 264 | 0.280 |
Why?
|
| Efficiency, Organizational | 2 | 2017 | 95 | 0.270 |
Why?
|
| Vaccinia | 1 | 2005 | 31 | 0.240 |
Why?
|
| Chloroquine | 1 | 2004 | 48 | 0.240 |
Why?
|
| United States | 8 | 2020 | 7516 | 0.230 |
Why?
|
| Botulinum Toxins | 1 | 2003 | 6 | 0.220 |
Why?
|
| Influenza, Human | 4 | 2013 | 193 | 0.220 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2003 | 5 | 0.220 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 1997 | 137 | 0.220 |
Why?
|
| Africa South of the Sahara | 2 | 2014 | 17 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 4 | 2018 | 724 | 0.190 |
Why?
|
| Vaccines, Conjugate | 1 | 2021 | 18 | 0.190 |
Why?
|
| Immunity, Mucosal | 3 | 1999 | 46 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 5 | 2012 | 498 | 0.180 |
Why?
|
| HIV Antibodies | 4 | 1999 | 141 | 0.180 |
Why?
|
| HIV Envelope Protein gp120 | 5 | 2002 | 139 | 0.180 |
Why?
|
| DNA Probes | 2 | 2012 | 35 | 0.180 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2020 | 4 | 0.170 |
Why?
|
| Federal Government | 1 | 2020 | 20 | 0.170 |
Why?
|
| Masks | 1 | 2020 | 20 | 0.170 |
Why?
|
| Skin | 1 | 2003 | 356 | 0.170 |
Why?
|
| Time Factors | 2 | 2017 | 3578 | 0.170 |
Why?
|
| Government Regulation | 1 | 2020 | 44 | 0.170 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 2 | 2011 | 10 | 0.170 |
Why?
|
| Anti-Infective Agents | 2 | 2012 | 139 | 0.170 |
Why?
|
| History, 19th Century | 2 | 2012 | 42 | 0.160 |
Why?
|
| Endotoxins | 2 | 2010 | 79 | 0.160 |
Why?
|
| Hospitalization | 2 | 2017 | 1283 | 0.160 |
Why?
|
| Alpha-Globulins | 2 | 2011 | 4 | 0.160 |
Why?
|
| History, 21st Century | 2 | 2012 | 162 | 0.150 |
Why?
|
| Decision Making, Organizational | 1 | 2017 | 26 | 0.150 |
Why?
|
| Fever | 1 | 2018 | 63 | 0.150 |
Why?
|
| Retrospective Studies | 2 | 2020 | 6007 | 0.140 |
Why?
|
| Back Pain | 1 | 2018 | 51 | 0.140 |
Why?
|
| Patient Dropouts | 1 | 2017 | 48 | 0.140 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 411 | 0.140 |
Why?
|
| Hospitals | 1 | 2020 | 375 | 0.140 |
Why?
|
| Aged | 5 | 2020 | 13342 | 0.140 |
Why?
|
| Virus Diseases | 2 | 2012 | 111 | 0.140 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 2 | 2013 | 26 | 0.140 |
Why?
|
| Genes, nef | 1 | 1996 | 6 | 0.130 |
Why?
|
| Patient Admission | 1 | 2017 | 185 | 0.130 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2013 | 88 | 0.130 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 1995 | 5 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 454 | 0.120 |
Why?
|
| Mycobacterium haemophilum | 1 | 1994 | 5 | 0.120 |
Why?
|
| Contrast Media | 1 | 2017 | 413 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 1094 | 0.120 |
Why?
|
| Mycobacterium Infections | 1 | 1994 | 16 | 0.120 |
Why?
|
| Molecular Sequence Data | 9 | 2011 | 1975 | 0.120 |
Why?
|
| Poliovirus | 1 | 2014 | 5 | 0.110 |
Why?
|
| Poliovirus Vaccines | 1 | 2014 | 4 | 0.110 |
Why?
|
| Health Education | 1 | 2015 | 184 | 0.110 |
Why?
|
| Massachusetts | 1 | 2020 | 2095 | 0.110 |
Why?
|
| Female | 16 | 2018 | 30895 | 0.110 |
Why?
|
| Public Health Surveillance | 1 | 2014 | 29 | 0.110 |
Why?
|
| Immunomodulation | 1 | 2013 | 27 | 0.110 |
Why?
|
| International Cooperation | 1 | 2014 | 81 | 0.110 |
Why?
|
| Drug Industry | 1 | 2014 | 40 | 0.110 |
Why?
|
| Patient Discharge | 1 | 2017 | 479 | 0.110 |
Why?
|
| Pilot Projects | 2 | 2015 | 922 | 0.110 |
Why?
|
| Dacryocystitis | 1 | 1993 | 3 | 0.110 |
Why?
|
| Tracheal Diseases | 1 | 2013 | 8 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2013 | 29 | 0.110 |
Why?
|
| Bacterial Vaccines | 2 | 2010 | 90 | 0.110 |
Why?
|
| Eye Infections, Bacterial | 1 | 1993 | 5 | 0.110 |
Why?
|
| Peptide Fragments | 1 | 1995 | 352 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 299 | 0.110 |
Why?
|
| Lipopolysaccharides | 3 | 2010 | 645 | 0.110 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1993 | 14 | 0.110 |
Why?
|
| Male | 14 | 2018 | 27561 | 0.110 |
Why?
|
| Adult | 16 | 2013 | 15771 | 0.100 |
Why?
|
| Bacteriology | 1 | 2012 | 1 | 0.100 |
Why?
|
| Antitoxins | 1 | 2012 | 2 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 525 | 0.100 |
Why?
|
| Thailand | 6 | 1999 | 94 | 0.100 |
Why?
|
| Phylogeny | 4 | 1998 | 332 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 38 | 0.100 |
Why?
|
| Herpesvirus 1, Cercopithecine | 1 | 1991 | 1 | 0.090 |
Why?
|
| Veterinary Medicine | 1 | 1991 | 3 | 0.090 |
Why?
|
| Viruses | 1 | 2012 | 79 | 0.090 |
Why?
|
| Base Sequence | 5 | 2011 | 1311 | 0.090 |
Why?
|
| Herpesviridae Infections | 1 | 1991 | 28 | 0.090 |
Why?
|
| Disaster Planning | 2 | 2008 | 51 | 0.090 |
Why?
|
| Research | 1 | 2012 | 191 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 740 | 0.090 |
Why?
|
| Spleen | 3 | 2011 | 485 | 0.090 |
Why?
|
| Cells, Cultured | 2 | 2005 | 2099 | 0.090 |
Why?
|
| Tularemia | 1 | 2010 | 17 | 0.090 |
Why?
|
| Francisella tularensis | 1 | 2010 | 23 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2012 | 231 | 0.080 |
Why?
|
| Middle Aged | 6 | 2018 | 16259 | 0.080 |
Why?
|
| Biological Warfare Agents | 1 | 2008 | 2 | 0.080 |
Why?
|
| RNA | 1 | 2012 | 403 | 0.080 |
Why?
|
| Occupational Diseases | 1 | 1991 | 266 | 0.080 |
Why?
|
| Rescue Work | 1 | 2008 | 15 | 0.080 |
Why?
|
| Vaccines, Attenuated | 1 | 2008 | 35 | 0.080 |
Why?
|
| Cyclonic Storms | 1 | 2008 | 23 | 0.080 |
Why?
|
| Sex Work | 2 | 1999 | 21 | 0.080 |
Why?
|
| Disaster Medicine | 1 | 2008 | 7 | 0.070 |
Why?
|
| Macrophages, Peritoneal | 2 | 2005 | 73 | 0.070 |
Why?
|
| Animals | 9 | 2011 | 19649 | 0.070 |
Why?
|
| Frail Elderly | 1 | 2008 | 110 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2010 | 553 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2013 | 904 | 0.070 |
Why?
|
| Inflammation | 1 | 2013 | 1097 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2010 | 879 | 0.070 |
Why?
|
| Internal Medicine | 1 | 2008 | 149 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 847 | 0.070 |
Why?
|
| Immunoglobulin A | 3 | 2010 | 93 | 0.070 |
Why?
|
| Furin | 1 | 2005 | 5 | 0.060 |
Why?
|
| Alzheimer Disease | 1 | 2011 | 556 | 0.060 |
Why?
|
| Pericarditis | 1 | 2005 | 8 | 0.060 |
Why?
|
| History, 18th Century | 1 | 2005 | 8 | 0.060 |
Why?
|
| Neutralization Tests | 1 | 2005 | 125 | 0.060 |
Why?
|
| Amino Acid Sequence | 6 | 1998 | 1578 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2008 | 312 | 0.060 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2004 | 43 | 0.060 |
Why?
|
| Immunoglobulin G | 3 | 2010 | 452 | 0.060 |
Why?
|
| Leukocyte Count | 1 | 2004 | 94 | 0.060 |
Why?
|
| Child | 1 | 2014 | 4308 | 0.060 |
Why?
|
| Young Adult | 1 | 2014 | 4321 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2005 | 670 | 0.050 |
Why?
|
| Cell Death | 1 | 2004 | 268 | 0.050 |
Why?
|
| Rats | 1 | 2007 | 1914 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2005 | 305 | 0.050 |
Why?
|
| Soft Tissue Infections | 1 | 2003 | 43 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 796 | 0.050 |
Why?
|
| Cell Survival | 1 | 2004 | 557 | 0.050 |
Why?
|
| Nursing Homes | 1 | 2008 | 665 | 0.050 |
Why?
|
| Monocytes | 1 | 2004 | 345 | 0.050 |
Why?
|
| Botulism | 1 | 2002 | 1 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2005 | 250 | 0.050 |
Why?
|
| Chronic Disease | 3 | 2013 | 736 | 0.050 |
Why?
|
| Neutrophils | 1 | 2004 | 351 | 0.050 |
Why?
|
| Education, Medical, Continuing | 1 | 2002 | 98 | 0.050 |
Why?
|
| Neoplasms | 1 | 2011 | 1244 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 1997 | 448 | 0.050 |
Why?
|
| Mice | 4 | 2011 | 10274 | 0.050 |
Why?
|
| HIV Envelope Protein gp160 | 2 | 1999 | 6 | 0.050 |
Why?
|
| Bacterial Infections | 1 | 2002 | 138 | 0.040 |
Why?
|
| DNA, Viral | 3 | 1996 | 228 | 0.040 |
Why?
|
| Cervix Uteri | 2 | 1999 | 57 | 0.040 |
Why?
|
| Asia | 2 | 1996 | 16 | 0.040 |
Why?
|
| Internet | 1 | 2003 | 460 | 0.040 |
Why?
|
| Receptors, CCR5 | 1 | 1999 | 57 | 0.040 |
Why?
|
| Travel | 2 | 1995 | 31 | 0.040 |
Why?
|
| Sexual Behavior | 2 | 1999 | 183 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2004 | 2068 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 1997 | 16 | 0.040 |
Why?
|
| Parotid Gland | 1 | 1997 | 11 | 0.030 |
Why?
|
| Genitalia, Female | 1 | 1997 | 19 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 1997 | 76 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 1997 | 112 | 0.030 |
Why?
|
| Genes, gag | 1 | 1996 | 11 | 0.030 |
Why?
|
| Genes, env | 1 | 1996 | 15 | 0.030 |
Why?
|
| Mosaicism | 1 | 1996 | 25 | 0.030 |
Why?
|
| Adolescent | 2 | 2005 | 5917 | 0.030 |
Why?
|
| Uruguay | 1 | 1995 | 1 | 0.030 |
Why?
|
| Cambodia | 1 | 1995 | 18 | 0.030 |
Why?
|
| Liver | 2 | 2011 | 784 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1996 | 358 | 0.030 |
Why?
|
| Viral Envelope Proteins | 1 | 1996 | 108 | 0.030 |
Why?
|
| Rifampin | 1 | 1994 | 23 | 0.030 |
Why?
|
| DNA, Ribosomal | 1 | 1994 | 29 | 0.030 |
Why?
|
| Ciprofloxacin | 1 | 1994 | 20 | 0.030 |
Why?
|
| ADP Ribose Transferases | 1 | 1994 | 62 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2005 | 5174 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1994 | 51 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1995 | 385 | 0.030 |
Why?
|
| Abscess | 1 | 1994 | 75 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1995 | 237 | 0.030 |
Why?
|
| Escherichia coli Infections | 1 | 1994 | 87 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 2013 | 43 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 1995 | 397 | 0.030 |
Why?
|
| Dacryocystorhinostomy | 1 | 1993 | 2 | 0.030 |
Why?
|
| Nasolacrimal Duct | 1 | 1993 | 2 | 0.030 |
Why?
|
| Fatty Acids | 1 | 1994 | 194 | 0.030 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 1993 | 7 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 1994 | 432 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 1994 | 260 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 2013 | 35 | 0.030 |
Why?
|
| Pulmonary Ventilation | 1 | 2013 | 36 | 0.030 |
Why?
|
| Seasons | 1 | 2013 | 130 | 0.030 |
Why?
|
| Spirometry | 1 | 2013 | 94 | 0.030 |
Why?
|
| Antibodies, Bacterial | 2 | 2010 | 193 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2013 | 64 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 192 | 0.030 |
Why?
|
| Genetic Variation | 1 | 1995 | 364 | 0.030 |
Why?
|
| Anaplasmataceae | 1 | 1992 | 1 | 0.030 |
Why?
|
| Rickettsiaceae Infections | 1 | 1992 | 5 | 0.030 |
Why?
|
| Arachnid Vectors | 1 | 1992 | 8 | 0.030 |
Why?
|
| DNA, Single-Stranded | 1 | 2013 | 100 | 0.030 |
Why?
|
| DNA Ligases | 1 | 2012 | 4 | 0.030 |
Why?
|
| Ligase Chain Reaction | 1 | 2012 | 2 | 0.030 |
Why?
|
| Ticks | 1 | 1992 | 30 | 0.030 |
Why?
|
| Prevalence | 1 | 1995 | 1284 | 0.020 |
Why?
|
| Aza Compounds | 1 | 2011 | 3 | 0.020 |
Why?
|
| Quinolines | 1 | 2011 | 38 | 0.020 |
Why?
|
| Fluoroquinolones | 1 | 2011 | 30 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 242 | 0.020 |
Why?
|
| Serum | 1 | 2010 | 34 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 1991 | 247 | 0.020 |
Why?
|
| Limulus Test | 1 | 1989 | 1 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2010 | 57 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2010 | 97 | 0.020 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 1989 | 13 | 0.020 |
Why?
|
| Aminoglycosides | 1 | 1989 | 9 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 2011 | 231 | 0.020 |
Why?
|
| Escherichia coli | 1 | 1994 | 685 | 0.020 |
Why?
|
| Algorithms | 1 | 1995 | 992 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 453 | 0.020 |
Why?
|
| Temperature | 1 | 2011 | 299 | 0.020 |
Why?
|
| HIV Seronegativity | 2 | 1999 | 18 | 0.020 |
Why?
|
| Louisiana | 1 | 2008 | 18 | 0.020 |
Why?
|
| Florida | 1 | 2008 | 40 | 0.020 |
Why?
|
| Hybridization, Genetic | 1 | 2008 | 14 | 0.020 |
Why?
|
| Molecular Epidemiology | 2 | 1998 | 26 | 0.020 |
Why?
|
| Competency-Based Education | 1 | 2008 | 28 | 0.020 |
Why?
|
| Problem-Based Learning | 1 | 2008 | 35 | 0.020 |
Why?
|
| Thermodynamics | 1 | 2008 | 194 | 0.020 |
Why?
|
| Patient Simulation | 1 | 2008 | 66 | 0.020 |
Why?
|
| Genotype | 2 | 1999 | 637 | 0.020 |
Why?
|
| Lung | 1 | 2010 | 833 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2010 | 749 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2002 | 99 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2002 | 147 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2008 | 731 | 0.010 |
Why?
|
| Needle Sharing | 1 | 1999 | 13 | 0.010 |
Why?
|
| Malaysia | 1 | 1998 | 2 | 0.010 |
Why?
|
| Risk Factors | 2 | 1999 | 5010 | 0.010 |
Why?
|
| Body Fluids | 1 | 1999 | 21 | 0.010 |
Why?
|
| Genes, MHC Class I | 1 | 1999 | 28 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 1999 | 48 | 0.010 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 1999 | 22 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 5098 | 0.010 |
Why?
|
| Vagina | 1 | 1999 | 82 | 0.010 |
Why?
|
| Korea | 1 | 1997 | 3 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1997 | 92 | 0.010 |
Why?
|
| Serotyping | 1 | 1996 | 50 | 0.010 |
Why?
|
| Nucleic Acid Heteroduplexes | 1 | 1996 | 14 | 0.010 |
Why?
|
| Genes, pol | 1 | 1996 | 1 | 0.010 |
Why?
|
| HIV Long Terminal Repeat | 1 | 1996 | 12 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1996 | 28 | 0.010 |
Why?
|
| Africa | 1 | 1996 | 21 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1996 | 111 | 0.010 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 1996 | 22 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1996 | 82 | 0.010 |
Why?
|
| Enhancer Elements, Genetic | 1 | 1996 | 100 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1999 | 1055 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 1996 | 156 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1999 | 1225 | 0.010 |
Why?
|
| O Antigens | 1 | 1994 | 4 | 0.010 |
Why?
|
| Exotoxins | 1 | 1994 | 9 | 0.010 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1994 | 43 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1994 | 111 | 0.010 |
Why?
|
| NF-kappa B | 1 | 1996 | 461 | 0.010 |
Why?
|
| Binding Sites | 1 | 1996 | 873 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 1996 | 659 | 0.010 |
Why?
|
| Peptides | 1 | 1996 | 545 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1994 | 501 | 0.010 |
Why?
|
| Cohort Studies | 1 | 1999 | 2443 | 0.010 |
Why?
|
| Prospective Studies | 1 | 1997 | 3096 | 0.010 |
Why?
|